测量肌痛严重症治疗不良事件负担:使用不良事件单位 (AEU) 进行单中心前性评估
Michael K Hehir1, Mark Conaway2, Avery B St Sauveur1
1Department of Neurological Sciences, University of Vermont College of Medicine, Burlington, Vermont, USA.
Muscle & nerve
|September 7, 2023
概括
不良事件单元 (AEU) 对测量肌痛性硬化症 (MG) 患者的药物副作用负担有希望. 这种工具在临床环境中是可行的和有效的.
科学领域:
- 神经学 神经学
- 临床药理学 临床药理学
- 患者报告的结果
背景情况:
- 骨髓灰质炎 (MG) 管理包括平衡治疗疗效与不良事件 (AE) 负担.
- 量化和比较MG中不同药物的AE负担是具有挑战性的.
- 为满足这一需求,开发了一种新型患者和医生权重的不良事件单元 (AEU).
研究的目的:
- 评估不良事件单元 (AEU) 的初步有效性和可行性,以测量患有严重肌痛症 (MG) 的成年患者的AE负担.
- 评估AEU的表现与已建立的MG结果指标相比.
主要方法:
- 一个单中心,前性,为期一年的观察性研究,涉及成年MG患者.
- 在日常访问中收集了AEU,MG-日常生活活动 (MG-ADL),MG-生活质量15项修订 (MG-QOL15r) 和MG-复合分数.
- 主要可行性终点:与MG-ADL相比,AEU的完成率.
- 评估了AEU给药时间,与MG-QOL15r的相关性,以及不同MG药物的AEU得分.
主要成果:
- 该研究达到其主要可行性终点,AEU和MG-ADL的完成率为100%.
- AEU的施用时间 (中位数为5分钟) 与MG-ADL/MG-QOL15r.相似.
- 在AEU和MG-QOL15r分数之间观察到弱但具有统计意义的相关性 (0.29).
- 在这个队列中,在不同的MG药物之间没有发现AE负担的统计学上显著差异.
结论:
- 不良事件单元 (AEU) 证明了在严重肌痛性肌痛症中量化AE负担的初步可行性和有效性.
- 可以有效地将AEU整合到MG患者的常规临床实践中.
- 需要进一步的研究来比较特定的MG治疗中的AE负担,并建立具有临床意义的AEU得分值.
相关概念视频
Myasthenia Gravis: Diagnostic Tests
978
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
978
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K


